Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation

被引:16
作者
Xu, Gaoqi [1 ]
Zhu, Liqin [2 ]
Ge, Tingyue [1 ]
Liao, Shasha [1 ]
Li, Na [1 ]
Qi, Fang [1 ]
机构
[1] Tianjin Med Univ, Basic Med Coll, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China
[2] Tianjin First Cent Hosp, Dept Pharm, 24 Fukang Rd, Tianjin 300192, Peoples R China
关键词
Voriconazole; Candida spp; Aspergillus spp; Children; Adolescents; Adults; POPULATION PHARMACOKINETIC ANALYSIS; EPIDEMIOLOGIC CUTOFF VALUES; TARGET ATTAINMENT; SAFETY;
D O I
10.1016/j.ijantimicag.2016.02.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The objective of this study was to investigate the cumulative fraction of response of various voriconazole dosing regimens against six Candida and six Aspergillus spp. in immunocompromised children, immunocompromised adolescents, and adults. Using pharmacokinetic parameters and pharmacodynamic data, 5000-subject Monte Carlo simulations (MCSs) were conducted to evaluate the ability of simulated dosing strategies in terms of fAUC/MIC targets of voriconazole. According to the results of the MCSs, current voriconazole dosage regimens were all effective for children, adolescents and adults against Candida albicans, Candida parapsilosis and Candida orthopsilosis. For adults, dosing regimens of 4 mg/kg intravenous every 12 h (q12h) and 300 mg orally q12h were sufficient to treat fungal infections by six Candida spp. (C. albicans, C. parapsilosis, Candida tropicalis, Candida glabrata, Candida krusei and C. orthopsilosis) and five Aspergillus spp. (Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, Aspergillus niger and Aspergillus nidulans). However, high doses should be recommended for children and adolescents in order to achieve better clinical efficacy against A. fumigatus and A. nidulans. The current voriconazole dosage regimens were all ineffective against A. niger for children and adolescents. All voriconazole dosage regimens were not optimal against Aspergillus versicolor. This is the first study to evaluate clinical therapy of various voriconazole dosing regimens against Candida and Aspergillus spp. infections in children, adolescents and adults using MCS. The pharmacokinetic/pharmacodynamic-based dosing strategy provided a theoretical rationale for identifying optimal voriconazole dosage regimens in children, adolescents and adults in order to maximise clinical response and minimise the probability of exposure-related toxicity. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:439 / 445
页数:7
相关论文
共 50 条
[21]   Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes [J].
Olczak-Kowalczyk, Dorota ;
Pyrzak, Beata ;
Dabkowska, Maria ;
Panczyk-Tomaszewska, Malgorzata ;
Miszkurka, Grazyna ;
Rogozinska, Izabela ;
Swoboda-Kopec, Ewa ;
Gozdowski, Dariusz ;
Kalinska, Angelika ;
Pirog, Anna ;
Mizerska-Wasiak, Malgorzata ;
Roszkowska-Blaim, Maria .
BMC ORAL HEALTH, 2015, 15
[22]   Antifungal activity of silver nanoparticles and clotrimazole against Candida spp. [J].
Laura Meneses, Maria ;
Recalde, Maite ;
Lorena Martin, Paula ;
Guillermo Pardo, Alejandro .
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58
[23]   Antifungal activity of the lemongrass oil and citral against Candida spp. [J].
da Silva, Cristiane de Bona ;
Guterres, Silvia S. ;
Weisheimer, Vanessa ;
Schapoval, Elfrides E. S. .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (01) :63-66
[24]   In Vitro Interactions Between Antifungals and Methotrexate Against Aspergillus spp. [J].
Yang, Jianxun ;
Wan, Zhe ;
Wang, Xiaohong ;
Liu, Wei ;
Li, Ruoyu .
MYCOPATHOLOGIA, 2009, 168 (05) :237-242
[25]   Support for the role of Candida spp. in extensive caries lesions of children [J].
Signoretto, Caterina ;
Burlacchini, Gloria ;
Faccioni, Fiorenzo ;
Zanderigo, Massimiliano ;
Bozzola, Nicolo ;
Caneparil, Pietro .
NEW MICROBIOLOGICA, 2009, 32 (01) :101-107
[26]   Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability [J].
Espinel-Ingroff, A. ;
Sasso, M. ;
Turnidge, J. ;
Arendrup, M. ;
Botterel, F. ;
Bourgeois, N. ;
Bouteille, B. ;
Canton, E. ;
Cassaing, S. ;
Dannaoui, E. ;
Dehais, M. ;
Delhaes, L. ;
Dupont, D. ;
Fekkar, A. ;
Fuller, J. ;
Garcia-Effron, G. ;
Garcia, J. ;
Gonzalez, G. M. ;
Govender, N. P. ;
Guegan, H. ;
Guinea, J. ;
Houze, S. ;
Lass-Florl, C. ;
Pelaez, T. ;
Forastiero, A. ;
Lackner, M. ;
Magobo, R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (11)
[27]   Voriconazole-natural latex dressings for treating infected Candida spp. skin ulcers [J].
da Silva, Thaina, V ;
de Barros, Natan R. ;
Costa-Orlandi, Caroline B. ;
Tanaka, Jean L. ;
Moro, Lincoln G. ;
Pegorin, Giovana S. ;
Oliveira, Kassandra S. M. ;
Mendes-Gianinni, Maria J. S. ;
Fusco-Almeida, Aria M. ;
Herculano, Rondinelli D. .
FUTURE MICROBIOLOGY, 2020, 15 (15) :1439-1452
[28]   In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest®:: results of a French multicentre study [J].
Mallié, M ;
Bastide, JM ;
Blancard, A ;
Bonnin, A ;
Bretagne, S ;
Cambon, M ;
Chandenier, J ;
Chauveau, V ;
Couprie, B ;
Datry, A ;
Feuilhade, M ;
Grillot, R ;
Guiguen, C ;
Lavarde, V ;
Letscher, V ;
Linas, MD ;
Michel, A ;
Morin, O ;
Paugam, A ;
Piens, MA ;
Raberin, H ;
Tissot, E ;
Toubas, D ;
Wade, A .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (04) :321-328
[29]   Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp. [J].
Roilides, E ;
Walsh, T .
MEDICAL MYCOLOGY, 2004, 42 (01) :1-13
[30]   Interaction of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro [J].
Perkhofer, Susanne ;
Niederegger, Harald ;
Blum, Gerhard ;
Burgstaller, Wolfgang ;
Ledochowski, Maximilian ;
Dierich, Manfred P. ;
Lass-Floerl, Cornelia .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (04) :424-429